Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT010 versus PT003 and PT009 for COPD exacerbations over 52 weeks
NL-OMON47721Phase 3Active, not recruiting
- Sponsor
- Pearl Therapeutics
- Start
- Feb 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide, glycopyrronium and formoterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Pearl Therapeutics. Primary endpoint: Rate of moderate or severe COPD exacerbations. Started Feb 2016; status: active, not recruiting.
02
Drugs
budesonideglycopyrroniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON47721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47721.